April 09, 2019
IRVING, Texas–(BUSINESS WIRE)–Over the last six years, the U.S. Food and Drug Administration has approved a number of highly innovative medical devices that have revolutionized cardiovascular care. These novel devices have provided advanced treatment options, improved quality of life and extended longevity for patients. Unfortunately, reimbursement has often failed to keep up with many of increasingly expensive treatment options. In the report, “The cost of medical device innovation: can we keep pace?” released today, Vizient looks at how hospitals must develop a systematic process that enables the evaluation and adoption of emerging technology in a way that benefits patients and providers in a financially sustainable way.
“A critical question facing providers is when they should implement an innovative technology. Physicians often want to be early adopters and have access to the latest technology because their goal is to always provide the best care for patients. But many potentially innovative technologies are never widely adopted for various reasons,” said Joe Cummings, technology program director for Vizient and a contributor to the white paper. “To use a value-based evaluation paradigm, the hospital’s technology adoption committee must engage in a systematic review of the clinical literature to determine pertinent clinical outcomes and also conduct financial analyses to estimate the total cost of care.”
Key findings from the report include:
- An average 273.3 percent increase in price over the predicate medical device was found in a review of Vizient data for several recent innovative cardiovascular medical device introductions.
- A review of select cardiovascular medical devices revealed considerable variability in the ratio of device cost to reimbursement. In fact, for some of the recent innovations, the device cost alone consumed a very high proportion of the overall reimbursement for the procedure, leaving minimal coverage for other expenses such as supplies, room costs and other miscellaneous resources required for the procedure.
- Hospitals, working collaboratively through multidisciplinary committees, must use a systematic, open and objective process focused on innovation assessments to determine which technologies provide better (optimal) patient care with improved value.
- Suppliers initially, then technology advocates, must provide better clinical data during the launch and early-adopter phases of a medical device introduction. The data must clearly demonstrate better outcomes to support informed decision-making by physicians and hospitals.
- Partnerships between providers and suppliers that allow for shared risk can help push both sides to improve quality and outcomes.
The report was compiled by Vizient, the largest member-driven healthcare performance improvement company in the country. The full report can be accessed here: https://newsroom.vizientinc.com/sites/vha.newshq.businesswire.com/files/doc_library/file/The_cost_of_medical_device_innovation.pdf
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2019, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com for more information about the company.